Enantioselective determination of Azelnidipine (cas 123524-52-7) in human plasma using liquid chromatography–tandem mass spectrometry
-
Add time:07/31/2019 Source:sciencedirect.com
A sensitive and simple method was developed for determination of the enantiomers of Azelnidipine (cas 123524-52-7), (R)-(−)-azelnidipine and (S)-(+)-azelnidipine, in human plasma using chiral liquid chromatography with positive ion atmospheric pressure chemical ionization tandem mass spectrometry. Plasma samples spiked with stable isotope-labeled azelnidipine, [2H6]-azelnidipine, as an internal standard, were processed for analysis using a solid-phase extraction in a 96-well plate format. The azelnidipine enantiomers were separated on a chiral column containing α1-acid glycoprotein as a chiral selector under isocratic mobile phase conditions. Acquisition of mass spectrometric data was performed in multiple reaction monitoring mode, monitoring the transitions from m/z 583 → 167 for (R)-(−)-azelnidipine and (S)-(+)-azelnidipine, and from m/z 589 → 167 for [2H6]-azelnidipine. The standard curve was linear over the studied range (0.05–20 ng/mL), with r2 > 0.997 using weighted (1/x2) quadratic regression, and the chromatographic run time was 5.0 min/injection. The intra- and inter-assay precision (coefficient of variation), calculated from the assay data of the quality control samples, was 1.2–8.2% and 2.4–5.8% for (R)-(−)-azelnidipine and (S)-(+)-azelnidipine, respectively. The accuracy was 101.2–117.0% for (R)-(−)-azelnidipine and 100.0–107.0% for (S)-(+)-azelnidipine. The overall recoveries for (R)-(−)-azelnidipine and (S)-(+)-azelnidipine were 71.4–79.7% and 71.7–84.2%, respectively. The lower limit of quantification for both enantiomers was 0.05 ng/mL using 1.0 mL of plasma. All the analytes showed acceptable short-term, long-term, auto-sampler and stock solution stability. Furthermore, the method described above was used to separately measure the concentrations of the azelnidipine enantiomers in plasma samples collected from healthy subjects who had received a single oral dose of 16 mg of azelnidipine.
We also recommend Trading Suppliers and Manufacturers of Azelnidipine (cas 123524-52-7). Pls Click Website Link as below: cas 123524-52-7 suppliers
Prev:Effect of Azelnidipine (cas 123524-52-7) and amlodipine on single cell mechanics in mouse cardiomyocytes
Next:Spectroscopic studies on the interaction of Azelnidipine (cas 123524-52-7) with bovine serum albumin) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Spectroscopic studies on the interaction of Azelnidipine (cas 123524-52-7) with bovine serum albumin08/01/2019
- Effect of Azelnidipine (cas 123524-52-7) and amlodipine on single cell mechanics in mouse cardiomyocytes07/30/2019
- Acute effects of intravenous nifedipine or Azelnidipine (cas 123524-52-7) on open-loop baroreflex static characteristics in rats07/29/2019
- Olmesartan with Azelnidipine (cas 123524-52-7) versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus07/28/2019
- Solid state characterization of Azelnidipine (cas 123524-52-7)–oxalic acid co-crystal and co-amorphous complexes: The effect of different Azelnidipine (cas 123524-52-7) polymorphs07/27/2019
- Inhibitory effects of losartan and Azelnidipine (cas 123524-52-7) on augmentation of blood pressure variability induced by angiotensin II in rats07/26/2019
- Limonin alleviates macro- and micro-vascular complications of metabolic syndrome in rats: A comparative study with Azelnidipine (cas 123524-52-7)07/25/2019
- Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by Azelnidipine (cas 123524-52-7) and manidipine07/24/2019
- Improved bioavailability of Azelnidipine (cas 123524-52-7) gastro retentive tablets-optimization and in-vivo assessment07/23/2019